Metabolic and Bariatric Surgery · 29 January 2024

Study Finds Over Half of ESG Patients Require Opioids in the Perioperative Setting

A retrospective study on endoscopic sleeve gastroplasty (ESG) evaluated the need for peri- and postoperative opioid therapy. Of the 67 patients included, 58.2% required opioids in the perioperative setting, with a mean dose of 12.3 mg morphine milligram equivalents (MMEs). Furthermore, 17.9% of patients required home opioid prescriptions postoperatively, while more than a third reported no pain. The study emphasizes the importance of individualizing opioid therapy to minimize overprescription and the risk of opioid overuse in ESG patients.

Journal Article by Moy BM, Volk S (…) Schulman AR et 2 al. in Am J Gastroenterol

read the whole article in Am J Gastroenterol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Metabolic and Bariatric Surgery.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Surg Endosc29 Sep 2026

Endoscopic Sleeve Gastroplasty Offers Safer Alternative to LSG

Endoscopic sleeve gastroplasty (ESG) provides moderate weight loss with a lower risk of complications compared to laparoscopic sleeve gastrectomy (LSG), making it a viable option for patients, particularly those with existing gastro-esophageal reflux disease (GERD).

Ann Surg13 Jul 2026

Predictive Models Enhance Diabetes Remission After Surgery

A new calculator predicts type 2 diabetes remission outcomes for patients post-metabolic surgery, improving patient selection.

Ann Surg16 Jun 2026

EndoBarrier Shows Promise for Type 2 Diabetes in Obesity

Endoscopic duodenal-jejunal bypass liner may significantly improve glycemic control and weight loss in patients with poorly controlled type 2 diabetes and obesity.

All papers in Metabolic and Bariatric Surgery →